Annual Current Liabilities
$967.79 M
+$199.87 M+26.03%
31 December 2023
Summary:
Alnylam Pharmaceuticals annual total current liabilities is currently $967.79 million, with the most recent change of +$199.87 million (+26.03%) on 31 December 2023. During the last 3 years, it has risen by +$382.52 million (+65.36%). ALNY annual current liabilities is now at all-time high.ALNY Current Liabilities Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Quarterly Current Liabilities
$1.22 B
+$165.41 M+15.68%
30 September 2024
Summary:
Alnylam Pharmaceuticals quarterly total current liabilities is currently $1.22 billion, with the most recent change of +$165.41 million (+15.68%) on 30 September 2024. Over the past year, it has increased by +$270.88 million (+28.52%). ALNY quarterly current liabilities is now at all-time high.ALNY Quarterly Current Liabilities Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
ALNY Current Liabilities Performance
| PeriodPeriod | AnnualAnnual | QuarterlyQuarterly |
|---|---|---|
| 1 y1 year | +26.0% | +28.5% |
| 3 y3 years | +65.4% | +99.9% |
| 5 y5 years | +439.2% | +245.9% |
ALNY Current Liabilities High & Low
| PeriodPeriod | Annual vs highAnnual vs high | Annual vs lowAnnual vs low | Quarter. vs highQuarter. vs high | Quarter. vs lowQuarter. vs low | |
|---|---|---|---|---|---|
| 3 y | 3 years | at high | +65.4% | at high | +101.4% |
| 5 y | 5 years | at high | +439.2% | at high | +260.3% |
| alltime | all time | at high | >+9999.0% | at high | >+9999.0% |
Alnylam Pharmaceuticals Current Liabilities History
| Date | Annual | Quarterly |
|---|---|---|
| Sept 2024 | - | $1.22 B(+15.7%) |
| June 2024 | - | $1.06 B(+12.1%) |
| Mar 2024 | - | $941.71 M(-2.7%) |
| Dec 2023 | $967.79 M(+26.0%) | $967.79 M(+1.9%) |
| Sept 2023 | - | $949.78 M(+20.4%) |
| June 2023 | - | $788.64 M(+17.1%) |
| Mar 2023 | - | $673.39 M(-12.3%) |
| Dec 2022 | $767.91 M(+10.4%) | $767.91 M(-0.6%) |
| Sept 2022 | - | $772.79 M(+17.5%) |
| June 2022 | - | $657.68 M(+8.5%) |
| Mar 2022 | - | $605.96 M(-12.9%) |
| Dec 2021 | $695.71 M(+18.9%) | $695.71 M(+13.9%) |
| Sept 2021 | - | $610.66 M(+10.1%) |
| June 2021 | - | $554.65 M(+12.1%) |
| Mar 2021 | - | $494.82 M(-15.5%) |
| Dec 2020 | $585.27 M(+66.0%) | $585.27 M(+21.9%) |
| Sept 2020 | - | $480.24 M(+25.0%) |
| June 2020 | - | $384.30 M(+13.4%) |
| Mar 2020 | - | $338.79 M(-3.9%) |
| Dec 2019 | $352.59 M(+96.4%) | $352.59 M(-0.1%) |
| Sept 2019 | - | $352.86 M(+7.4%) |
| June 2019 | - | $328.60 M(+120.3%) |
| Mar 2019 | - | $149.16 M(-16.9%) |
| Dec 2018 | $179.49 M(+24.4%) | $179.49 M(+47.7%) |
| Sept 2018 | - | $121.50 M(+6.9%) |
| June 2018 | - | $113.66 M(-1.5%) |
| Mar 2018 | - | $115.38 M(-20.0%) |
| Dec 2017 | $144.25 M(+9.5%) | $144.25 M(+42.8%) |
| Sept 2017 | - | $101.05 M(-7.1%) |
| June 2017 | - | $108.73 M(+13.5%) |
| Mar 2017 | - | $95.79 M(-27.3%) |
| Dec 2016 | $131.70 M(+112.1%) | $131.70 M(+61.1%) |
| Sept 2016 | - | $81.76 M(+15.8%) |
| June 2016 | - | $70.58 M(+6.3%) |
| Mar 2016 | - | $66.37 M(+6.9%) |
| Dec 2015 | $62.10 M(-34.9%) | $62.10 M(+8.7%) |
| Sept 2015 | - | $57.11 M(-14.2%) |
| June 2015 | - | $66.60 M(-17.5%) |
| Mar 2015 | - | $80.69 M(-15.4%) |
| Dec 2014 | $95.33 M | $95.33 M(+67.7%) |
| Sept 2014 | - | $56.85 M(+5.8%) |
| June 2014 | - | $53.74 M(-35.9%) |
| Date | Annual | Quarterly |
|---|---|---|
| Mar 2014 | - | $83.83 M(+55.6%) |
| Dec 2013 | $53.86 M(+11.4%) | $53.86 M(-1.9%) |
| Sept 2013 | - | $54.90 M(+3.4%) |
| June 2013 | - | $53.07 M(+6.7%) |
| Mar 2013 | - | $49.75 M(+2.9%) |
| Dec 2012 | $48.34 M(-40.3%) | $48.34 M(-11.7%) |
| Sept 2012 | - | $54.76 M(-4.0%) |
| June 2012 | - | $57.06 M(-14.4%) |
| Mar 2012 | - | $66.64 M(-17.7%) |
| Dec 2011 | $80.99 M(-20.6%) | $80.99 M(-13.8%) |
| Sept 2011 | - | $93.93 M(-6.6%) |
| June 2011 | - | $100.53 M(+1.2%) |
| Mar 2011 | - | $99.34 M(-2.6%) |
| Dec 2010 | $102.05 M(-7.8%) | $102.05 M(+2.6%) |
| Sept 2010 | - | $99.43 M(-2.5%) |
| June 2010 | - | $102.03 M(+3.5%) |
| Mar 2010 | - | $98.57 M(-11.0%) |
| Dec 2009 | $110.73 M(+11.3%) | $110.73 M(+9.5%) |
| Sept 2009 | - | $101.12 M(-1.2%) |
| June 2009 | - | $102.33 M(-1.8%) |
| Mar 2009 | - | $104.25 M(+4.8%) |
| Dec 2008 | $99.45 M(+19.1%) | $99.45 M(-2.5%) |
| Sept 2008 | - | $102.02 M(-3.5%) |
| June 2008 | - | $105.73 M(+24.5%) |
| Mar 2008 | - | $84.91 M(+1.7%) |
| Dec 2007 | $83.48 M(+264.1%) | $83.48 M(-4.5%) |
| Sept 2007 | - | $87.46 M(+222.6%) |
| June 2007 | - | $27.11 M(+15.4%) |
| Mar 2007 | - | $23.50 M(+2.5%) |
| Dec 2006 | $22.93 M(+24.0%) | $22.93 M(+6.5%) |
| Sept 2006 | - | $21.53 M(+4.5%) |
| June 2006 | - | $20.60 M(+3.1%) |
| Mar 2006 | - | $19.99 M(+8.1%) |
| Dec 2005 | $18.48 M(+181.1%) | $18.48 M(+131.0%) |
| Sept 2005 | - | $8.00 M(-11.3%) |
| June 2005 | - | $9.02 M(+47.0%) |
| Mar 2005 | - | $6.14 M(-6.6%) |
| Dec 2004 | $6.58 M(+71.0%) | $6.58 M(-1.0%) |
| Sept 2004 | - | $6.64 M(-23.7%) |
| June 2004 | - | $8.70 M(+6.2%) |
| Mar 2004 | - | $8.19 M(+113.1%) |
| Dec 2003 | $3.84 M(+43.8%) | $3.84 M |
| Dec 2002 | $2.67 M | - |
FAQ
- What is Alnylam Pharmaceuticals annual total current liabilities?
- What is the all time high annual current liabilities for Alnylam Pharmaceuticals?
- What is Alnylam Pharmaceuticals annual current liabilities year-on-year change?
- What is Alnylam Pharmaceuticals quarterly total current liabilities?
- What is the all time high quarterly current liabilities for Alnylam Pharmaceuticals?
- What is Alnylam Pharmaceuticals quarterly current liabilities year-on-year change?
What is Alnylam Pharmaceuticals annual total current liabilities?
The current annual current liabilities of ALNY is $967.79 M
What is the all time high annual current liabilities for Alnylam Pharmaceuticals?
Alnylam Pharmaceuticals all-time high annual total current liabilities is $967.79 M
What is Alnylam Pharmaceuticals annual current liabilities year-on-year change?
Over the past year, ALNY annual total current liabilities has changed by +$199.87 M (+26.03%)
What is Alnylam Pharmaceuticals quarterly total current liabilities?
The current quarterly current liabilities of ALNY is $1.22 B
What is the all time high quarterly current liabilities for Alnylam Pharmaceuticals?
Alnylam Pharmaceuticals all-time high quarterly total current liabilities is $1.22 B
What is Alnylam Pharmaceuticals quarterly current liabilities year-on-year change?
Over the past year, ALNY quarterly total current liabilities has changed by +$270.88 M (+28.52%)